Fundraising Fox
Visgenx
San Diego, US · Founded 2018 · Delaware corporation · 1 employees on LinkedIn · 1 known investors
Find your way into Visgenx
Sign up to see every warm intro you have to Visgenx
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Visgenx team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Developing therapeutics, including gene therapy, for dry Age-Related Macular Degeneration.
Founders & leadership
SV
Santosh VetticadenNamed on SEC filing
ME
Martin EmanueleNamed on SEC filing
FD
Frank DouglasNamed on SEC filing
Investors · 1
Reported raises · per SEC filings
Form D private placements$9.2M disclosed across 3 rounds · 2019–2023
▶$2.8MraisedJun 2023 · 17 investors · BiotechnologyRule 506(b)
▶$2.8MraisedJun 2023 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Martin Emanuele, Ph.D.Executive Officer, Director
- Thomas Meier, Ph.D., M.D.Director
- Elaine Heron, Ph.D.Director
- William PedrantiExecutive Officer, Director
- Arthur BeckerDirector
- Santosh Vetticaden, Ph.D., M.D.Director
- Eric Carter, Ph.D., M.D.Director
- Offering amount
- $3.5M
- Amount sold
- $2.8M
- First sale
- Jun 2023
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$5.7MraisedAug 2020 · 30 investors · BiotechnologyRule 506(b)
▶$5.7MraisedAug 2020 · 30 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Martin Emanuele, Ph.D.Executive Officer, Director
- Santosh Vetticaden, M.D., Ph.D., MBAExecutive Officer, Director
- Elaine Heron, Ph.D.Director
- Arthur BeckerDirector
- Frank Douglas, M.D., Ph.D.Director
- Offering amount
- $5.7M
- Amount sold
- $5.7M
- First sale
- May 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$655KraisedJul 2019 · 4 investors · BiotechnologyRule 506(b)
▶$655KraisedJul 2019 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Santosh VetticadenExecutive Officer, Director
- Martin EmanueleExecutive Officer, Director
- Frank DouglasDirector
- Offering amount
- $2.2M
- Amount sold
- $655K
- First sale
- Jul 2019
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Visgenx do?
- Developing therapeutics, including gene therapy, for dry Age-Related Macular Degeneration.
- Who are Visgenx's investors?
- Visgenx's investors include Cove Fund.
- How much funding has Visgenx raised?
- Visgenx has disclosed $9.2M raised across 3 rounds.
- Where is Visgenx headquartered?
- Visgenx is headquartered in San Diego, US.